Valuation: Clarity Pharmaceuticals Ltd

Capitalization 1.1B 728M 626M 586M 546M 1.01B 65.5B 6.86B 2.65B 30.94B 2.73B 2.67B 113B P/E ratio 2026 *
-13.8x
P/E ratio 2027 * -12.7x
Enterprise value 910M 603M 519M 486M 453M 837M 54.31B 5.68B 2.19B 25.65B 2.26B 2.22B 93.79B EV / Sales 2026 *
-
EV / Sales 2027 * 22.5x
Free-Float
73.99%
Yield 2026 *
-
Yield 2027 * -
More valuation ratios * Estimated data
Dynamic Chart
1 day-2.96%
1 week-18.28%
Current month-18.28%
1 month-35.02%
3 months-6.94%
6 months+31.11%
Current year-29.26%
More quotes
1 week 2.91
Extreme 2.91
3.54
1 month 2.91
Extreme 2.91
4.95
Current year 1.43
Extreme 1.43
5.87
1 year 1.43
Extreme 1.43
5.98
3 years 0.68
Extreme 0.675
8.98
5 years 0.36
Extreme 0.36
8.98
10 years 0.36
Extreme 0.36
8.98
More quotes
Manager TitleAgeSince
Chief Executive Officer - 11/10/2024
Chief Executive Officer - 01/01/2010
Director of Finance/CFO - 04/04/2022
Director TitleAgeSince
Chairman - 01/11/2013
Director/Board Member - 01/10/2010
Director/Board Member 71 29/03/2016
More insiders
Change 5d. change 1-year change 3-years change Capi.($)
-2.96%-18.28%-46.56%+205.70% 750M
+1.63%+1.48%+33.90%+109.24% 54.89B
-2.02%-5.24%+175.31%+975.36% 43.51B
+1.27%+0.39%+65.79%+16.06% 38.12B
+1.47%+0.20%-19.24%-43.20% 23.14B
+1.18%+0.64%+31.67%-36.48% 19.5B
+0.98%+5.71%+89.97%-35.16% 17.25B
+0.24%+1.22%+90.80%+236.22% 14.68B
+1.17%+7.24%-0.80%+412.74% 14.12B
-3.09%-2.32%+142.02% - 13.78B
Average -0.01%-1.49%+56.29%+204.50% 23.98B
Weighted average by Cap. +0.41%-0.43%+70.76%+248.60%
See all sector performances

Financials

2026 *2027 *
Net sales - 43.86M 29.08M 25M 23.42M 21.83M 40.32M 2.62B 274M 106M 1.24B 109M 107M 4.52B
Net income -74.67M -49.52M -42.57M -39.88M -37.17M -68.65M -4.46B -466M -180M -2.1B -186M -182M -7.7B -81.43M -54M -46.42M -43.49M -40.53M -74.86M -4.86B -509M -196M -2.3B -203M -198M -8.39B
Net Debt -187M -124M -107M -100M -93.33M -172M -11.19B -1.17B -452M -5.29B -467M -457M -19.32B -111M -73.86M -63.49M -59.48M -55.44M -102M -6.65B -696M -269M -3.14B -277M -271M -11.48B
More financial data * Estimated data
Logo Clarity Pharmaceuticals Ltd
Clarity Pharmaceuticals Ltd is an Australia-based clinical-stage radiopharmaceutical company. The Company is focused on developing theranostic (therapy and imaging) products, based on its platform SAR Technology. It is progressing seven clinical trials with its three key products, SARTATE, SAR-bisPSMA, and SAR-Bombesin. SARTATE is developed for diagnosing, staging, and treating cancers that express somatostatin receptor 2 (SSTR2), including neuroblastoma and neuroendocrine tumors (NETs). SAR-bisPSMA is developed for diagnosing, staging, and treating cancers that express Prostate Specific Membrane Antigen (PSMA). SAR-Bombesin is developed for identifying and selecting patients for subsequent treatment of cancers that express a specific receptor called the gastrin releasing peptide receptor (GRPr), including breast cancer and prostate cancer. It has a diverse range of products in clinical trials, which address both large indications as well as rare and orphan indications of cancer.
Employees
69
More about the company
Date Price Change Volume
08/12/25 2.950 $ -2.96% 2,280,468
05/12/25 3.040 $ 0.00% 1,910,795
04/12/25 3.040 $ -5.30% 2,332,822
03/12/25 3.210 $ -3.89% 1,435,189
02/12/25 3.340 $ -4.30% 2,204,865

Delayed Quote Australian S.E., 08 December 2025 at 04:10 pm AEDT

More quotes
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
4
Last Close Price
2.950AUD
Average target price
7.400AUD
Spread / Average Target
+150.85%
Consensus

Annual profits - Rate of surprise